L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

This study tests a combination of tumor-infiltrating lymphocytes (TILs) — immune cells taken from the patient's own tumor — plus a checkpoint immunotherapy drug called tislelizumab, in people with advanced non-small cell lung cancer (NSCLC) whose cancer stopped responding to a prior PD-1 antibody immunotherapy. **You may be eligible if...** - You have been diagnosed with stage IV non-small cell lung cancer confirmed by biopsy - Your cancer progressed during or after a prior anti-PD-1 immunotherapy - Non-squamous cancer patients must have no EGFR, ALK, ROS1, RET, or MET mutations - You have at least one measurable tumor on scans - Your general health is good (ECOG 0–1) - Your organ function (blood, liver, kidneys) is adequate **You may NOT be eligible if...** - Your cancer is small cell lung cancer or mixed type including small cell - You have had another cancer diagnosis within the past 5 years - You are currently in another clinical trial - You have active autoimmune disease or are on steroids/immunosuppressants - You have organ transplant history or active hepatitis B/C - You are pregnant or breastfeeding - You have symptomatic brain metastases or uncontrolled infections Talk to your doctor to see if this trial is right for you.